H.C. Wainwright lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $22 from $25 and keeps a Buy rating on the shares. The firm cites Ojemda’s trajectory for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Buy Rating Backed by Strong Ojemda Outperformance, Reaffirmed 2026 Revenue Outlook, and Pipeline Clinical Catalysts
- Day One Highlights Transformational 2025 and OJEMDA Growth
- Day One Biopharmaceuticals reports Q4 revenue $52.8M, consensus $49.81M
- Day One backs FY26 revenue view $225M-$250M, consensus $236.56M
- DAWN Upcoming Earnings Report: What to Expect?